{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:06:28Z","timestamp":1789023988028,"version":"build-2803163510"},"reference-count":173,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sao Paulo Research Foundation","award":["2024\/10066-3"],"award-info":[{"award-number":["2024\/10066-3"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of the Review<\/jats:title>\n                    <jats:p>This review summarizes obesity-induced adaptations in subcutaneous and visceral white adipose tissue (WAT) depots and discusses how incretin-based pharmacotherapies and bariatric surgery may influence WAT remodeling beyond weight loss, drawing on evidence from animal models and human studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>In obesity, adipose tissue undergoes pathological remodeling characterized by structural and cellular changes, extracellular matrix (ECM) remodeling, altered endocrine signaling, and impaired mitochondrial function that contribute to metabolic comorbidities. Weight-loss interventions, including incretin-based therapies and bariatric surgery, are associated with improvements in adiposity and metabolic outcomes, and multiple studies suggest accompanying changes in inflammatory, mitochondrial\/thermogenic, and endocrine pathways within WAT; however, mechanistic evidence in humans remains heterogeneous and is often limited by tissue accessibility and study design.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>This review highlights candidate cellular and molecular mechanisms through which incretin-based pharmacotherapies and bariatric surgery may modulate WAT plasticity, emphasizing convergent and distinct effects across depots and the need for more longitudinal, tissue-level human studies to define weight-dependent remodeling versus changes not fully explained by weight loss.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s13679-026-00756-x","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:21:31Z","timestamp":1789021291000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adipose Tissue Remodeling Beyond Weight Loss: New Insights Into Incretin-Based Therapies and Bariatric Surgery"],"prefix":"10.1007","volume":"15","author":[{"given":"Gabriela Ferreira","family":"Abud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen Cristini","family":"de Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0681-7746","authenticated-orcid":false,"given":"Kristin I.","family":"Stanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"756_CR1","unstructured":"World Health Organization. WHO acceleration plan to stop obesity. Updated July 3. 2023. Accessed May 5, 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240075634"},{"key":"756_CR2","doi-asserted-by":"publisher","first-page":"104754","DOI":"10.1016\/j.compbiomed.2021.104754","volume":"136","author":"M Safaei","year":"2021","unstructured":"Safaei M, Sundararajan EA, Driss M, Boulila W, Shapi\u2019i A. A systematic literature review on obesity: understanding the causes and consequences of obesity and reviewing various machine learning approaches used to predict obesity. Comput Biol Med. 2021;136:104754. https:\/\/doi.org\/10.1016\/j.compbiomed.2021.104754.","journal-title":"Comput Biol Med"},{"issue":"20","key":"756_CR3","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1001\/jama.2023.19897","volume":"330","author":"A Elmaleh-Sachs","year":"2023","unstructured":"Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity management in adults: a review. JAMA. 2023;330(20):2000\u201315. https:\/\/doi.org\/10.1001\/jama.2023.19897.","journal-title":"JAMA"},{"issue":"3","key":"756_CR4","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.cmet.2023.02.002","volume":"35","author":"B Maniyadath","year":"2023","unstructured":"Maniyadath B, Zhang Q, Gupta RK, Mandrup S. Adipose tissue at single-cell resolution. Cell Metab. 2023;35(3):386\u2013413. https:\/\/doi.org\/10.1016\/j.cmet.2023.02.002.","journal-title":"Cell Metab"},{"issue":"6","key":"756_CR5","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","volume":"31","author":"RJ Samms","year":"2020","unstructured":"Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410\u201321. https:\/\/doi.org\/10.1016\/j.tem.2020.02.006.","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"756_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.7570\/jomes24013","volume":"33","author":"M Bl\u00fcher","year":"2024","unstructured":"Bl\u00fcher M. Understanding adipose tissue dysfunction. J Obes Metab Syndr. 2024;33(4):275\u201388. https:\/\/doi.org\/10.7570\/jomes24013.","journal-title":"J Obes Metab Syndr"},{"issue":"1\u20132","key":"756_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cell.2013.12.012","volume":"156","author":"ED Rosen","year":"2014","unstructured":"Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell. 2014;156(1\u20132):20\u201344. https:\/\/doi.org\/10.1016\/j.cell.2013.12.012.","journal-title":"Cell"},{"key":"756_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3389\/fcvm.2020.00022","volume":"7","author":"A Chait","year":"2020","unstructured":"Chait A, den Hartigh LJ. Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Front Cardiovasc Med. 2020;7:22. https:\/\/doi.org\/10.3389\/fcvm.2020.00022.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"756_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1152\/physrev.00015.2003","volume":"84","author":"B Cannon","year":"2004","unstructured":"Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev. 2004;84(1):277\u2013359. https:\/\/doi.org\/10.1152\/physrev.00015.2003.","journal-title":"Physiol Rev"},{"issue":"6","key":"756_CR10","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.2337\/db12-1430","volume":"62","author":"H Sacks","year":"2013","unstructured":"Sacks H, Symonds ME. Anatomical locations of human brown adipose tissue: functional relevance and implications in obesity and type 2 diabetes. Diabetes. 2013;62(6):1783\u201390. https:\/\/doi.org\/10.2337\/db12-1430.","journal-title":"Diabetes"},{"issue":"1","key":"756_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1080\/21623945.2020.1870060","volume":"10","author":"L Cheng","year":"2021","unstructured":"Cheng L, Wang J, Dai H, Duan Y, An Y, Shi L, et al. Brown and beige adipose tissue: a novel therapeutic strategy for obesity and type 2 diabetes mellitus. Adipocyte. 2021;10(1):48\u201365. https:\/\/doi.org\/10.1080\/21623945.2020.1870060.","journal-title":"Adipocyte"},{"key":"756_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1146\/annurev-pathol-042220-023633","volume":"18","author":"C Auger","year":"2023","unstructured":"Auger C, Kajimura S. Adipose tissue remodeling in pathophysiology. Annu Rev Pathol. 2023;18:71\u201393. https:\/\/doi.org\/10.1146\/annurev-pathol-042220-023633.","journal-title":"Annu Rev Pathol"},{"issue":"11","key":"756_CR13","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nrendo.2017.90","volume":"13","author":"SM Reilly","year":"2017","unstructured":"Reilly SM, Saltiel AR. Adapting to obesity with adipose tissue inflammation. Nat Rev Endocrinol. 2017;13(11):633\u201343. https:\/\/doi.org\/10.1038\/nrendo.2017.90.","journal-title":"Nat Rev Endocrinol"},{"key":"756_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.20517\/jca.2023.38","volume":"4","author":"F Gao","year":"2024","unstructured":"Gao F, Litchfield B, Wu H. Adipose tissue lymphocytes and obesity. J Cardiovasc Aging. 2024;4:5. https:\/\/doi.org\/10.20517\/jca.2023.38.","journal-title":"J Cardiovasc Aging"},{"issue":"7","key":"756_CR15","doi-asserted-by":"publisher","first-page":"e67709","DOI":"10.1371\/journal.pone.0067709","volume":"8","author":"VN Montes","year":"2013","unstructured":"Montes VN, Turner MS, Subramanian S, Ding Y, Hayden-Ledbetter M, Slater S, et al. T cell activation inhibitors reduce CD8\u2009+\u2009T cell and pro-inflammatory macrophage accumulation in adipose tissue of obese mice. PLoS ONE. 2013;8(7):e67709. https:\/\/doi.org\/10.1371\/journal.pone.0067709.","journal-title":"PLoS ONE"},{"issue":"5","key":"756_CR16","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/ijo.2014.195","volume":"39","author":"RL Travers","year":"2015","unstructured":"Travers RL, Motta AC, Betts JA, Bouloumi\u00e9 A, Thompson D. The impact of adiposity on adipose tissue-resident lymphocyte activation in humans. Int J Obes (Lond). 2015;39(5):762\u20139. https:\/\/doi.org\/10.1038\/ijo.2014.195.","journal-title":"Int J Obes (Lond)"},{"issue":"7","key":"756_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.tem.2015.05.006","volume":"26","author":"AS Williams","year":"2015","unstructured":"Williams AS, Kang L, Wasserman DH. The extracellular matrix and insulin resistance. Trends Endocrinol Metab. 2015;26(7):357\u201366. https:\/\/doi.org\/10.1016\/j.tem.2015.05.006.","journal-title":"Trends Endocrinol Metab"},{"issue":"6","key":"756_CR18","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1172\/JCI45887","volume":"121","author":"K Sun","year":"2011","unstructured":"Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clin Invest. 2011;121(6):2094\u2013101. https:\/\/doi.org\/10.1172\/JCI45887.","journal-title":"J Clin Invest"},{"issue":"2","key":"756_CR19","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1053\/j.gastro.2008.10.079","volume":"136","author":"R Menghini","year":"2009","unstructured":"Menghini R, Menini S, Amoruso R, Fiorentino L, Casagrande V, Marzano V, et al. Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology. 2009;136(2):663\u2013e6724. https:\/\/doi.org\/10.1053\/j.gastro.2008.10.079.","journal-title":"Gastroenterology"},{"issue":"3","key":"756_CR20","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2353\/ajpath.2009.081155","volume":"175","author":"A De Pauw","year":"2009","unstructured":"De Pauw A, Tejerina S, Raes M, Keijer J, Arnould T. Mitochondrial (dys)function in adipocyte (de)differentiation and systemic metabolic alterations. Am J Pathol. 2009;175(3):927\u201339. https:\/\/doi.org\/10.2353\/ajpath.2009.081155.","journal-title":"Am J Pathol"},{"issue":"9","key":"756_CR21","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.2337\/db14-1937","volume":"64","author":"S Heinonen","year":"2015","unstructured":"Heinonen S, Buzkova J, Muniandy M, Kaksonen R, Ollikainen M, Ismail K, et al. Impaired mitochondrial biogenesis in adipose tissue in acquired obesity. Diabetes. 2015;64(9):3135\u201345. https:\/\/doi.org\/10.2337\/db14-1937.","journal-title":"Diabetes"},{"key":"756_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11010-014-2236-7","volume":"399","author":"M Chattopadhyay","year":"2015","unstructured":"Chattopadhyay M, Khemka VK, Chatterjee G, et al. Enhanced ROS production and oxidative damage in subcutaneous white adipose tissue mitochondria in obese and type 2 diabetes subjects. Mol Cell Biochem. 2015;399:95\u2013103. https:\/\/doi.org\/10.1007\/s11010-014-2236-7.","journal-title":"Mol Cell Biochem"},{"issue":"2","key":"756_CR23","doi-asserted-by":"publisher","first-page":"e12958","DOI":"10.1111\/obr.12958","volume":"21","author":"S Heinonen","year":"2020","unstructured":"Heinonen S, Jokinen R, Rissanen A, Pietil\u00e4inen KH. White adipose tissue mitochondrial metabolism in health and in obesity. Obes Rev. 2020;21(2):e12958. https:\/\/doi.org\/10.1111\/obr.12958.","journal-title":"Obes Rev"},{"issue":"Pt 2","key":"756_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.intimp.2024.113499","volume":"25","author":"Y Xia","year":"2024","unstructured":"Xia Y, Jin J, Sun Y, Kong X, Shen Z, Yan R, Huang R, Liu X, Xia W, Ma J, Zhu X, Li Q, Ma J. Tirzepatide\u2019s role in targeting adipose tissue macrophages to reduce obesity-related inflammation and improve insulin resistance. Int Immunopharmacol. 2024;25(Pt 2):143. https:\/\/doi.org\/10.1016\/j.intimp.2024.113499.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"756_CR25","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2337\/db06-1135","volume":"56","author":"JX Rong","year":"2007","unstructured":"Rong JX, Qiu Y, Hansen MK, Zhu L, Zhang V, Xie M, et al. Adipose mitochondrial biogenesis is suppressed in db\/db and high-fat diet-fed mice and improved by rosiglitazone. Diabetes. 2007;56(7):1751\u201360. https:\/\/doi.org\/10.2337\/db06-1135.","journal-title":"Diabetes"},{"key":"756_CR26","doi-asserted-by":"publisher","first-page":"74364","DOI":"10.1155\/2007\/74364","volume":"2007","author":"F Villarroya","year":"2007","unstructured":"Villarroya F, Iglesias R, Giralt M. PPARs in the control of uncoupling proteins gene expression. PPAR Res. 2007;2007:74364. https:\/\/doi.org\/10.1155\/2007\/74364.","journal-title":"PPAR Res"},{"issue":"4","key":"756_CR27","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s00125-006-0170-2","volume":"49","author":"HJ Choo","year":"2006","unstructured":"Choo HJ, Kim JH, Kwon OB, Lee CS, Mun JY, Han SS, et al. Mitochondria are impaired in the adipocytes of type 2 diabetic mice. Diabetologia. 2006;49(4):784\u201391. https:\/\/doi.org\/10.1007\/s00125-006-0170-2.","journal-title":"Diabetologia"},{"issue":"2","key":"756_CR28","doi-asserted-by":"publisher","first-page":"E209","DOI":"10.1210\/jc.2013-3042","volume":"99","author":"X Yin","year":"2014","unstructured":"Yin X, Lanza IR, Swain JM, Sarr MG, Nair KS, Jensen MD. Adipocyte mitochondrial function is reduced in human obesity independent of fat cell size. J Clin Endocrinol Metab. 2014;99(2):E209\u201316. https:\/\/doi.org\/10.1210\/jc.2013-3042.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"756_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00125-016-4121-2","volume":"60","author":"S Heinonen","year":"2017","unstructured":"Heinonen S, Muniandy M, Buzkova J, Mardinoglu A, Rodr\u00edguez A, Fr\u00fchbeck G, et al. Mitochondria-related transcriptional signature is downregulated in adipocytes in obesity: a study of young healthy MZ twins. Diabetologia. 2017;60(1):169\u201381. https:\/\/doi.org\/10.1007\/s00125-016-4121-2.","journal-title":"Diabetologia"},{"issue":"10","key":"756_CR30","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1007\/s00125-007-0776-z","volume":"50","author":"JA Maassen","year":"2007","unstructured":"Maassen JA, Romijn JA, Heine RJ. Fatty acid-induced mitochondrial uncoupling in adipocytes as a key protective factor against insulin resistance and beta cell dysfunction: a new concept in the pathogenesis of obesity-associated type 2 diabetes mellitus. Diabetologia. 2007;50(10):2036\u201341. https:\/\/doi.org\/10.1007\/s00125-007-0776-z.","journal-title":"Diabetologia"},{"issue":"12","key":"756_CR31","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1016\/j.metabol.2011.04.015","volume":"60","author":"M Chattopadhyay","year":"2011","unstructured":"Chattopadhyay M, Guhathakurta I, Behera P, Ranjan KR, Khanna M, Mukhopadhyay S, et al. Mitochondrial bioenergetics is not impaired in nonobese subjects with type 2 diabetes mellitus. Metabolism. 2011;60(12):1702\u201310. https:\/\/doi.org\/10.1016\/j.metabol.2011.04.015.","journal-title":"Metabolism"},{"issue":"8","key":"756_CR32","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.arcmed.2008.09.005","volume":"39","author":"ME V\u00e1zquez-Vela","year":"2008","unstructured":"V\u00e1zquez-Vela ME, Torres N, Tovar AR. White adipose tissue as endocrine organ and its role in obesity. Arch Med Res. 2008;39(8):715\u201328. https:\/\/doi.org\/10.1016\/j.arcmed.2008.09.005.","journal-title":"Arch Med Res"},{"issue":"3","key":"756_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cmet.2007.08.010","volume":"6","author":"OA MacDougald","year":"2007","unstructured":"MacDougald OA, Burant CF. The rapidly expanding family of adipokines. Cell Metab. 2007;6(3):159\u201361. https:\/\/doi.org\/10.1016\/j.cmet.2007.08.010.","journal-title":"Cell Metab"},{"issue":"5","key":"756_CR34","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrm2391","volume":"9","author":"A Guilherme","year":"2008","unstructured":"Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9(5):367\u201377. https:\/\/doi.org\/10.1038\/nrm2391.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"756_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2302\/kjm.60.1","volume":"60","author":"JM Friedman","year":"2011","unstructured":"Friedman JM. Leptin and the regulation of body weight. Keio J Med. 2011;60(1):1\u20139. https:\/\/doi.org\/10.2302\/kjm.60.1.","journal-title":"Keio J Med"},{"key":"756_CR36","doi-asserted-by":"publisher","unstructured":"M\u00fcnzberg H, Singh P, Heymsfield SB, Yu S, Morrison CD. Recent advances in understanding the role of leptin in energy homeostasis. F1000Res. 2020;9. https:\/\/doi.org\/10.12688\/f1000research.24260.1. F1000 Faculty Rev","DOI":"10.12688\/f1000research.24260.1"},{"issue":"12","key":"756_CR37","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/nm1295-1311","volume":"1","author":"RC Frederich","year":"1995","unstructured":"Frederich RC, Hamann A, Anderson S, L\u00f6llmann B, Lowell BB, Flier JS. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med. 1995;1(12):1311\u20134. https:\/\/doi.org\/10.1038\/nm1295-1311.","journal-title":"Nat Med"},{"issue":"11","key":"756_CR38","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/nm1195-1155","volume":"1","author":"M Maffei","year":"1995","unstructured":"Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med. 1995;1(11):1155\u201361. https:\/\/doi.org\/10.1038\/nm1195-1155.","journal-title":"Nat Med"},{"issue":"8","key":"756_CR39","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.1074\/jbc.M008553200","volume":"276","author":"Y Lee","year":"2001","unstructured":"Lee Y, Wang MY, Kakuma T, Wang ZW, Babcock E, McCorkle K, et al. Liporegulation in diet-induced obesity: the antisteatotic role of hyperleptinemia. J Biol Chem. 2001;276(8):5629\u201335. https:\/\/doi.org\/10.1074\/jbc.M008553200.","journal-title":"J Biol Chem"},{"issue":"5","key":"756_CR40","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199602013340503","volume":"334","author":"RV Considine","year":"1996","unstructured":"Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334(5):292\u20135. https:\/\/doi.org\/10.1056\/NEJM199602013340503.","journal-title":"N Engl J Med"},{"issue":"8","key":"756_CR41","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.2337\/diacare.26.8.2442","volume":"26","author":"M Chandran","year":"2003","unstructured":"Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care. 2003;26(8):2442\u201350. https:\/\/doi.org\/10.2337\/diacare.26.8.2442.","journal-title":"Diabetes Care"},{"issue":"8","key":"756_CR42","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/90984","volume":"7","author":"T Yamauchi","year":"2001","unstructured":"Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7(8):941\u20136. https:\/\/doi.org\/10.1038\/90984.","journal-title":"Nat Med"},{"issue":"4","key":"756_CR43","doi-asserted-by":"publisher","first-page":"E1079","DOI":"10.1152\/ajpendo.00245.2006","volume":"292","author":"JW Bullen Jr","year":"2007","unstructured":"Bullen JW Jr, Bluher S, Kelesidis T, Mantzoros CS. Regulation of adiponectin and its receptors in response to development of diet-induced obesity in mice. Am J Physiol Endocrinol Metab. 2007;292(4):E1079\u201386. https:\/\/doi.org\/10.1152\/ajpendo.00245.2006. https:\/\/journals.physiology.org\/doi\/full\/.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"756_CR44","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/ijo.2015.181","volume":"40","author":"P Singh","year":"2016","unstructured":"Singh P, Sharma P, Sahakyan KR, Davison DE, Sert-Kuniyoshi FH, Romero-Corral A, et al. Differential effects of leptin on adiponectin expression with weight gain versus obesity. Int J Obes (Lond). 2016;40(2):266\u201374. https:\/\/doi.org\/10.1038\/ijo.2015.181.","journal-title":"Int J Obes (Lond)"},{"issue":"7","key":"756_CR45","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.2337\/diabetes.52.7.1779","volume":"52","author":"PA Kern","year":"2003","unstructured":"Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes. 2003;52(7):1779\u201385. https:\/\/doi.org\/10.2337\/diabetes.52.7.1779.","journal-title":"Diabetes"},{"issue":"10","key":"756_CR46","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1210\/jc.2007-2724","volume":"93","author":"CA Aguilar-Salinas","year":"2008","unstructured":"Aguilar-Salinas CA, Garc\u00eda EG, Robles L, Ria\u00f1o D, Ruiz-Gomez DG, Garc\u00eda-Ulloa AC, et al. High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab. 2008;93(10):4075\u20139. https:\/\/doi.org\/10.1210\/jc.2007-2724.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"756_CR47","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/ejcn.2011.35","volume":"65","author":"B Schautz","year":"2011","unstructured":"Schautz B, Later W, Heller M, M\u00fcller MJ, Bosy-Westphal A. Associations between breast adipose tissue, body fat distribution and cardiometabolic risk in women: cross-sectional data and weight-loss intervention. Eur J Clin Nutr. 2011;65(7):784\u201390. https:\/\/doi.org\/10.1038\/ejcn.2011.35.","journal-title":"Eur J Clin Nutr"},{"key":"756_CR48","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13098-017-0293-2","volume":"9","author":"MI Jonas","year":"2017","unstructured":"Jonas MI, Kurylowicz A, Bartoszewicz Z, Lisik W, Jonas M, Domienik-Karlowicz J, et al. Adiponectin\/resistin interplay in serum and in adipose tissue of obese and normal-weight individuals. Diabetol Metab Syndr. 2017;9:95. https:\/\/doi.org\/10.1186\/s13098-017-0293-2.","journal-title":"Diabetol Metab Syndr"},{"issue":"7049","key":"756_CR49","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature03711","volume":"436","author":"Q Yang","year":"2005","unstructured":"Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436(7049):356\u201362. https:\/\/doi.org\/10.1038\/nature03711.","journal-title":"Nature"},{"issue":"24","key":"756_CR50","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1056\/NEJMoa054862","volume":"354","author":"TE Graham","year":"2006","unstructured":"Graham TE, Yang Q, Bl\u00fcher M, Hammarstedt A, Ciaraldi TP, Henry RR, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006;354(24):2552\u201363. https:\/\/doi.org\/10.1056\/NEJMoa054862.","journal-title":"N Engl J Med"},{"issue":"10","key":"756_CR51","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.2337\/db06-0616","volume":"55","author":"J Janke","year":"2006","unstructured":"Janke J, Engeli S, Boschmann M, Adams F, B\u00f6hnke J, Luft FC, et al. Retinol-binding protein 4 in human obesity. Diabetes. 2006;55(10):2805\u201310. https:\/\/doi.org\/10.2337\/db06-0616.","journal-title":"Diabetes"},{"issue":"12","key":"756_CR52","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.2337\/db06-1647","volume":"56","author":"P Kovacs","year":"2007","unstructured":"Kovacs P, Geyer M, Berndt J, Kl\u00f6ting N, Graham TE, B\u00f6ttcher Y, et al. Effects of genetic variation in the human retinol binding protein-4 gene (RBP4) on insulin resistance and fat depot-specific mRNA expression. Diabetes. 2007;56(12):3095\u2013100. https:\/\/doi.org\/10.2337\/db06-1647.","journal-title":"Diabetes"},{"issue":"6","key":"756_CR53","doi-asserted-by":"publisher","first-page":"927","DOI":"10.33549\/physiolres.931379","volume":"57","author":"M Bajzov\u00e1","year":"2008","unstructured":"Bajzov\u00e1 M, Kov\u00e1\u010dikov\u00e1 M, V\u00edtkov\u00e1 M, Klim\u010d\u00e1kov\u00e1 E, Pol\u00e1k J, Kov\u00e1\u010dov\u00e1 Z, et al. Retinol-binding protein 4 expression in visceral and subcutaneous fat in human obesity. Physiol Res. 2008;57(6):927\u201334. https:\/\/doi.org\/10.33549\/physiolres.931379.","journal-title":"Physiol Res"},{"issue":"1","key":"756_CR54","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2337\/db08-1019","volume":"58","author":"R Ribel-Madsen","year":"2009","unstructured":"Ribel-Madsen R, Friedrichsen M, Vaag A, Poulsen P. Retinol-binding protein 4 in twins: regulatory mechanisms and impact of circulating and tissue expression levels on insulin secretion and action. Diabetes. 2009;58(1):54\u201360. https:\/\/doi.org\/10.2337\/db08-1019.","journal-title":"Diabetes"},{"issue":"1","key":"756_CR55","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/nyas.14211","volume":"1461","author":"CW Chia","year":"2020","unstructured":"Chia CW, Egan JM. Incretins in obesity and diabetes. Ann N Y Acad Sci. 2020;1461(1):104\u201326. https:\/\/doi.org\/10.1111\/nyas.14211.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"756_CR56","doi-asserted-by":"publisher","first-page":"e13531","DOI":"10.1111\/obr.13531","volume":"24","author":"MI Aukan","year":"2023","unstructured":"Aukan MI, Coutinho S, Pedersen SA, Simpson MR, Martins C. Differences in gastrointestinal hormones and appetite ratings between individuals with and without obesity-A systematic review and meta-analysis. Obes Rev. 2023;24(2):e13531. https:\/\/doi.org\/10.1111\/obr.13531.","journal-title":"Obes Rev"},{"issue":"6","key":"756_CR57","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","volume":"17","author":"JE Campbell","year":"2013","unstructured":"Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819\u201337. https:\/\/doi.org\/10.1016\/j.cmet.2013.04.008.","journal-title":"Cell Metab"},{"key":"756_CR58","doi-asserted-by":"publisher","first-page":"170183","DOI":"10.1016\/j.peptides.2019.170183","volume":"125","author":"LS Gasbjerg","year":"2020","unstructured":"Gasbjerg LS, Bergmann NC, Stensen S, Christensen MB, Rosenkilde MM, Holst JJ, et al. Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides. 2020;125:170183. https:\/\/doi.org\/10.1016\/j.peptides.2019.170183.","journal-title":"Peptides"},{"issue":"5","key":"756_CR59","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2337\/db21-1166","volume":"71","author":"JE Campbell","year":"2022","unstructured":"Campbell JE, Beaudry JL, Svendsen B, Baggio LL, Gordon AN, Ussher JR, et al. GIPR is predominantly localized to nonadipocyte cell types within white adipose tissue. Diabetes. 2022;71(5):1115\u201327. https:\/\/doi.org\/10.2337\/db21-1166.","journal-title":"Diabetes"},{"issue":"9","key":"756_CR60","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S2213-8587(21)00179-0","volume":"9","author":"IJ Neeland","year":"2021","unstructured":"Neeland IJ, Marso SP, Ayers CR, Lewis B, Oslica R, Francis W, et al. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled clinical trial. Lancet Diabetes Endocrinol. 2021;9(9):595\u2013605. https:\/\/doi.org\/10.1016\/S2213-8587(21)00179-0.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"756_CR61","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, STEP 5 Study Group, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083\u201391. https:\/\/doi.org\/10.1038\/s41591-022-02026-4.","journal-title":"Nat Med"},{"issue":"2","key":"756_CR62","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, et al. STEP 8 Investigators. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138\u201350. https:\/\/doi.org\/10.1001\/jama.2021.23619.","journal-title":"JAMA"},{"issue":"19","key":"756_CR63","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1001\/jama.2024.2603","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ. SURMOUNT-4 Investigators. Tirzepatide for maintenance of weight reduction in adults with obesity\u2014reply. JAMA. 2024;331(19):1676. https:\/\/doi.org\/10.1001\/jama.2024.2603.","journal-title":"JAMA"},{"issue":"6","key":"756_CR64","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2337\/dc24-2425","volume":"48","author":"VR Aroda","year":"2025","unstructured":"Aroda VR, J\u00f8rgensen NB, Kumar B, Lingvay I, Laulund AS, Buse JB, et al. trial investigators. High-dose semaglutide (up to 16\u00a0mg) in people with type 2 diabetes and overweight or obesity: a randomized, placebo-controlled, phase 2 trial. Diabetes Care. 2025;48(6):905\u201313. https:\/\/doi.org\/10.2337\/dc24-2425.","journal-title":"Diabetes Care"},{"issue":"5","key":"756_CR65","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1053\/j.gastro.2022.08.045","volume":"163","author":"E Grunvald","year":"2022","unstructured":"Grunvald E, Shah R, Hernaez R, Chandar AK, Pickett-Blakely O, Teigen LM, et al. AGA Clinical Guidelines Committee. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163(5):1198\u2013225. https:\/\/doi.org\/10.1053\/j.gastro.2022.08.045.","journal-title":"Gastroenterology"},{"key":"756_CR66","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/164_2015_6","volume":"233","author":"M Giralt","year":"2016","unstructured":"Giralt M, Cereijo R, Villarroya F. Adipokines and the endocrine role of adipose tissues. Handb Exp Pharmacol. 2016;233:265\u201382. https:\/\/doi.org\/10.1007\/164_2015_6.","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"756_CR67","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s13679-025-00660-w","volume":"14","author":"F Villarroya","year":"2025","unstructured":"Villarroya F, Peyrou M, Giralt M. Adipose tissue, at the core of the action of incretin and glucagon-based anti-obesity drugs. Curr Obes Rep. 2025;14(1):67. https:\/\/doi.org\/10.1007\/s13679-025-00660-w.","journal-title":"Curr Obes Rep"},{"issue":"1","key":"756_CR68","doi-asserted-by":"publisher","first-page":"6274","DOI":"10.1038\/s41598-019-42770-1","volume":"18","author":"M Ejarque","year":"2019","unstructured":"Ejarque M, Guerrero-P\u00e9rez F, de la Morena N, Casajoana A, Virgili N, L\u00f3pez-Urdiales R, et al. Role of adipose tissue GLP-1R expression in metabolic improvement after bariatric surgery in patients with type 2 diabetes. Sci Rep. 2019;18(1):6274. https:\/\/doi.org\/10.1038\/s41598-019-42770-1.","journal-title":"Sci Rep"},{"issue":"11","key":"756_CR69","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1210\/en.2011-1070","volume":"152","author":"J Vendrell","year":"2011","unstructured":"Vendrell J, El Bekay R, Peral B, Garc\u00eda-Fuentes E, Megia A, Macias-Gonzalez M, et al. Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology. 2011;152(11):4072\u20139. https:\/\/doi.org\/10.1210\/en.2011-1070.","journal-title":"Endocrinology"},{"issue":"6","key":"756_CR70","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1210\/jcem.77.6.8263154","volume":"77","author":"E M\u00e9rida","year":"1993","unstructured":"M\u00e9rida E, Delgado E, Molina LM, Villanueva-Pe\u00f1acarrillo ML, Valverde I. Presence of glucagon and glucagon-like peptide-1-(7\u201336) amide receptors in solubilized membranes of human adipose tissue. J Clin Endocrinol Metab. 1993;77(6):1654\u20137. https:\/\/doi.org\/10.1210\/jcem.77.6.8263154.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"756_CR71","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/(SICI)1097-4652(199709)172:3<275::AID-JCP1>3.0.CO;2-L","volume":"172","author":"C Montrose-Rafizadeh","year":"1997","unstructured":"Montrose-Rafizadeh C, Yang H, Wang Y, Roth J, Montrose MH, Adams LG. Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. J Cell Physiol. 1997;172(3):275\u2013. https:\/\/doi.org\/10.1002\/(SICI)1097-4652(199709)172:3%3C275::AID-JCP1%3E3.0.CO;2-L. 83.","journal-title":"J Cell Physiol"},{"issue":"9","key":"756_CR72","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.2337\/dbi18-0008","volume":"67","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications. Diabetes. 2018;67(9):1710\u20139. https:\/\/doi.org\/10.2337\/dbi18-0008.","journal-title":"Diabetes"},{"issue":"Pt 5","key":"756_CR73","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1242\/jcs.02792","volume":"119","author":"A Baudry","year":"2006","unstructured":"Baudry A, Yang ZZ, Hemmings BA. PKBalpha is required for adipose differentiation of mouse embryonic fibroblasts. J Cell Sci. 2006;119(Pt 5):889\u201397. https:\/\/doi.org\/10.1242\/jcs.02792.","journal-title":"J Cell Sci"},{"issue":"3","key":"756_CR74","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1074\/jbc.M109.067207","volume":"285","author":"J Quoyer","year":"2010","unstructured":"Quoyer J, Longuet C, Broca C, Linck N, Costes S, Varin E, et al. GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1\/2 activation in pancreatic beta-cells. J Biol Chem. 2010;285(3):1989\u20132002. https:\/\/doi.org\/10.1074\/jbc.M109.067207.","journal-title":"J Biol Chem"},{"issue":"9","key":"756_CR75","doi-asserted-by":"publisher","first-page":"6421","DOI":"10.1074\/jbc.M111.310342","volume":"287","author":"TD Challa","year":"2012","unstructured":"Challa TD, Beaton N, Arnold M, Rudofsky G, Langhans W, Wolfrum C. Regulation of adipocyte formation by GLP-1\/GLP-1R signaling. J Biol Chem. 2012;287(9):6421\u201330. https:\/\/doi.org\/10.1074\/jbc.M111.310342.","journal-title":"J Biol Chem"},{"issue":"10","key":"756_CR76","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41580-020-0255-7","volume":"21","author":"H Lavoie","year":"2020","unstructured":"Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 2020;21(10):607\u201332. https:\/\/doi.org\/10.1038\/s41580-020-0255-7.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"756_CR77","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.biochi.2004.10.018","volume":"87","author":"F Bost","year":"2005","unstructured":"Bost F, Aouadi M, Caron L, Bin\u00e9truy B. The role of MAPKs in adipocyte differentiation and obesity. Biochimie. 2005;87(1):51\u20136. https:\/\/doi.org\/10.1016\/j.biochi.2004.10.018.","journal-title":"Biochimie"},{"issue":"1","key":"756_CR78","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1006\/bbrc.1995.2753","volume":"217","author":"D Lacasa","year":"1995","unstructured":"Lacasa D, Agli B, Giudicelli Y. Zeta PKC in rat preadipocytes: modulation by insulin and serum mitogenic factors and possible role in adipogenesis. Biochem Biophys Res Commun. 1995;217(1):123\u201330. https:\/\/doi.org\/10.1006\/bbrc.1995.2753.","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"756_CR79","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/cbf.3751","volume":"40","author":"FF Martins","year":"2022","unstructured":"Martins FF, Marinho TS, Cardoso LEM, Barbosa-da-Silva S, Souza-Mello V, Aguila MB, et al. Semaglutide (GLP-1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice. Cell Biochem Funct. 2022;40(8):903\u201313. https:\/\/doi.org\/10.1002\/cbf.3751.","journal-title":"Cell Biochem Funct"},{"issue":"5","key":"756_CR80","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1042\/CS20160803","volume":"131","author":"E Pastel","year":"2017","unstructured":"Pastel E, McCulloch LJ, Ward R, Joshi S, Gooding KM, Shore AC, et al. GLP-1 analogue-induced weight loss does not improve obesity-induced adipose tissue dysfunction. Clin Sci (Lond). 2017;131(5):343\u201353. https:\/\/doi.org\/10.1042\/CS20160803.","journal-title":"Clin Sci (Lond)"},{"issue":"10","key":"756_CR81","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1111\/dom.14090","volume":"22","author":"H Ghanim","year":"2020","unstructured":"Ghanim H, Batra M, Green K, Abuaysheh S, Hejna J, Makdissi A, et al. Liraglutide treatment in overweight and obese patients with type 1 diabetes: a 26-week randomized controlled trial; mechanisms of weight loss. Diabetes Obes Metab. 2020;22(10):1742\u201352. https:\/\/doi.org\/10.1111\/dom.14090.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"756_CR82","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/bcpt.13575","volume":"128","author":"AM Wegeberg","year":"2021","unstructured":"Wegeberg AM, Meldgaard T, Baek A, Drewes AM, Vyberg M, Jessen N, et al. Subcutaneous adipose tissue composition and function are unaffected by liraglutide-induced weight loss in adults with type 1 diabetes. Basic Clin Pharmacol Toxicol. 2021;128(6):773\u201382. https:\/\/doi.org\/10.1111\/bcpt.13575.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"756_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-023-02096-9","volume":"23","author":"D Garc\u00eda-Vega","year":"2024","unstructured":"Garc\u00eda-Vega D, S\u00e1nchez-L\u00f3pez D, Rodr\u00edguez-Carnero G, Villar-Taibo R, Vi\u00f1uela JE, Lesteg\u00e1s-Soto A, et al. Semaglutide modulates prothrombotic and atherosclerotic mechanisms associated with epicardial fat, neutrophils and endothelial cells network. Cardiovasc Diabetol. 2024;23(1):1. https:\/\/doi.org\/10.1186\/s12933-023-02096-9.","journal-title":"Cardiovasc Diabetol"},{"issue":"Suppl 3","key":"756_CR84","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4137\/CMC","volume":"8","author":"M Furuhashi","year":"2015","unstructured":"Furuhashi M, Saitoh S, Shimamoto K, Miura T. Fatty acid-binding protein 4 (FABP4): pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases. Clin Med Insights Cardiol. 2015;8(Suppl 3):23\u201333. https:\/\/doi.org\/10.4137\/CMC.","journal-title":"Clin Med Insights Cardiol"},{"key":"756_CR85","doi-asserted-by":"publisher","first-page":"100185","DOI":"10.1016\/j.crphar.2024.100185","volume":"6","author":"V Touceda","year":"2024","unstructured":"Touceda V, Fontana Estevez F, Cacciagi\u00fa L, Finocchietto P, Bustos R, Vidal A, et al. Liraglutide improves adipose tissue remodeling and mitochondrial dynamics in a visceral obesity model induced by a high-fat diet. Curr Res Pharmacol Drug Discov. 2024;6:100185. https:\/\/doi.org\/10.1016\/j.crphar.2024.100185.","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"2","key":"756_CR86","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12020-018-1826-7","volume":"64","author":"J Zhou","year":"2019","unstructured":"Zhou J, Poudel A, Chandramani-Shivalingappa P, Xu B, Welchko R, Li L. Liraglutide induces beige fat development and promotes mitochondrial function in diet-induced obesity mice partially through AMPK-SIRT-1-PGC1-\u03b1 signaling pathway. Endocrine. 2019;64(2):271\u201383. https:\/\/doi.org\/10.1007\/s12020-018-1826-7.","journal-title":"Endocrine"},{"issue":"49","key":"756_CR87","doi-asserted-by":"publisher","first-page":"81077","DOI":"10.18632\/oncotarget.13189","volume":"7","author":"E Zhu","year":"2016","unstructured":"Zhu E, Yang Y, Zhang J, Li Y, Li C, Chen L, et al. Liraglutide suppresses obesity and induces brown fat-like phenotype via soluble guanylyl cyclase mediated pathway in vivo and in vitro. Oncotarget. 2016;7(49):81077\u201389. https:\/\/doi.org\/10.18632\/oncotarget.13189.","journal-title":"Oncotarget"},{"key":"756_CR88","doi-asserted-by":"publisher","first-page":"110635","DOI":"10.1016\/j.diabres.2023.110635","volume":"199","author":"M Vaittinen","year":"2023","unstructured":"Vaittinen M, Ilha M, Herbers E, Wagner A, Virtanen KA, Pietil\u00e4inen KH, et al. Liraglutide demonstrates a therapeutic effect on mitochondrial dysfunction in human SGBS adipocytes in vitro. Diabetes Res Clin Pract. 2023;199:110635. https:\/\/doi.org\/10.1016\/j.diabres.2023.110635.","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"756_CR89","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.cell.2012.05.016","volume":"150","author":"J Wu","year":"2012","unstructured":"Wu J, Bostr\u00f6m P, Sparks LM, Ye L, Choi JH, Giang AH, et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell. 2012;150(2):366\u201376. https:\/\/doi.org\/10.1016\/j.cell.2012.05.016.","journal-title":"Cell"},{"issue":"5\u20136","key":"756_CR90","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.mam.2004.06.004","volume":"25","author":"JP Bonnefont","year":"2004","unstructured":"Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med. 2004;25(5\u20136):495\u2013520. https:\/\/doi.org\/10.1016\/j.mam.2004.06.004.","journal-title":"Mol Aspects Med"},{"issue":"5","key":"756_CR91","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10545-010-9061-2","volume":"33","author":"SM Houten","year":"2010","unstructured":"Houten SM, Wanders RJ. A general introduction to the biochemistry of mitochondrial fatty acid \u03b2-oxidation. J Inherit Metab Dis. 2010;33(5):469\u201377. https:\/\/doi.org\/10.1007\/s10545-010-9061-2.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"756_CR92","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.bbalip.2014.01.005","volume":"1841","author":"HM Nagy","year":"2014","unstructured":"Nagy HM, Paar M, Heier C, Moustafa T, Hofer P, Haemmerle G, et al. Adipose triglyceride lipase activity is inhibited by long-chain acyl-coenzyme A. Biochim Biophys Acta. 2014;1841(4):588\u201394. https:\/\/doi.org\/10.1016\/j.bbalip.2014.01.005.","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"756_CR93","doi-asserted-by":"publisher","first-page":"114501","DOI":"10.1016\/j.celrep.2024.114501","volume":"43","author":"JM Jacobsen","year":"2024","unstructured":"Jacobsen JM, Petersen N, Torz L, Gerstenberg MK, Pedersen K, \u00d8stergaard S, et al. Housing mice near vs below thermoneutrality affects drug-induced weight loss but does not improve prediction of efficacy in humans. Cell Rep. 2024;43(8):114501. https:\/\/doi.org\/10.1016\/j.celrep.2024.114501.","journal-title":"Cell Rep"},{"issue":"10","key":"756_CR94","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1507\/endocrj.EJ21-0802","volume":"69","author":"X Lyu","year":"2022","unstructured":"Lyu X, Yan K, Wang X, Xu H, Guo X, Zhu H, et al. A novel anti-obesity mechanism for liraglutide by improving adipose tissue leptin resistance in high-fat diet-fed obese mice. Endocr J. 2022;69(10):1233\u201344. https:\/\/doi.org\/10.1507\/endocrj.EJ21-0802.","journal-title":"Endocr J"},{"issue":"3","key":"756_CR95","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.bbrc.2009.10.015","volume":"390","author":"T Chung le","year":"2009","unstructured":"Chung le T, Hosaka T, Yoshida M, Harada N, Sakaue H, Sakai T, et al. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun. 2009;390(3):613\u20138. https:\/\/doi.org\/10.1016\/j.bbrc.2009.10.015.","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"756_CR96","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1139\/cjpp-2017-0650","volume":"96","author":"NAT Abbas","year":"2018","unstructured":"Abbas NAT, El Salem A. Metformin, sitagliptin, and liraglutide modulate serum retinol-binding protein-4 level and adipocytokine production in type 2 diabetes mellitus rat model. Can J Physiol Pharmacol. 2018;96(12):1226\u201331. https:\/\/doi.org\/10.1139\/cjpp-2017-0650.","journal-title":"Can J Physiol Pharmacol"},{"issue":"2","key":"756_CR97","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s12020-019-01891-3","volume":"64","author":"A Singh","year":"2019","unstructured":"Singh A, Fernandes JRD, Chhabra G, Krishna A, Banerjee A. Liraglutide modulates adipokine expression during adipogenesis, ameliorating obesity and polycystic ovary syndrome in mice. Endocrine. 2019;64(2):349\u201366. https:\/\/doi.org\/10.1007\/s12020-019-01891-3.","journal-title":"Endocrine"},{"issue":"6","key":"756_CR98","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1053\/j.gastro.2007.09.005","volume":"133","author":"DH Song","year":"2007","unstructured":"Song DH, Getty-Kaushik L, Tseng E, Simon J, Corkey BE, Wolfe MM. Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation. Gastroenterology. 2007;133(6):1796\u2013805. https:\/\/doi.org\/10.1053\/j.gastro.2007.09.005.","journal-title":"Gastroenterology"},{"issue":"7","key":"756_CR99","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.cmet.2024.05.010","volume":"36","author":"A Regmi","year":"2024","unstructured":"Regmi A, Aihara E, Christe ME, Varga G, Beyer TP, Ruan X, et al. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. Cell Metab. 2024;36(7):1534\u2013e15497. https:\/\/doi.org\/10.1016\/j.cmet.2024.05.010.","journal-title":"Cell Metab"},{"issue":"50","key":"756_CR100","doi-asserted-by":"publisher","first-page":"43062","DOI":"10.1074\/jbc.M111.289009","volume":"286","author":"S Mohammad","year":"2011","unstructured":"Mohammad S, Ramos LS, Buck J, Levin LR, Rubino F, McGraw TE. Gastric inhibitory peptide controls adipose insulin sensitivity via activation of cAMP-response element-binding protein and p110\u03b2 isoform of phosphatidylinositol 3-kinase. J Biol Chem. 2011;286(50):43062\u201370. https:\/\/doi.org\/10.1074\/jbc.M111.289009.","journal-title":"J Biol Chem"},{"issue":"11","key":"756_CR101","doi-asserted-by":"publisher","first-page":"113326","DOI":"10.1016\/j.celrep.2023.113326","volume":"42","author":"N Za\u00efmia","year":"2023","unstructured":"Za\u00efmia N, Obeid J, Varrault A, Sabatier J, Broca C, Gilon P, et al. GLP-1 and GIP receptors signal through distinct \u03b2-arrestin 2-dependent pathways to regulate pancreatic \u03b2 cell function. Cell Rep. 2023;42(11):113326. https:\/\/doi.org\/10.1016\/j.celrep.2023.113326.","journal-title":"Cell Rep"},{"issue":"7","key":"756_CR102","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1038\/s42255-024-01061-4","volume":"6","author":"HS Kizilkaya","year":"2024","unstructured":"Kizilkaya HS, S\u00f8rensen KV, Madsen JS, Lindquist P, Douros JD, Bork-Jensen J, et al. Characterization of genetic variants of GIPR reveals a contribution of \u03b2-arrestin to metabolic phenotypes. Nat Metab. 2024;6(7):1268\u201381. https:\/\/doi.org\/10.1038\/s42255-024-01061-4.","journal-title":"Nat Metab"},{"issue":"17","key":"756_CR103","doi-asserted-by":"publisher","first-page":"e140532","DOI":"10.1172\/jci.insight.140532","volume":"5","author":"FS Willard","year":"2020","unstructured":"Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. https:\/\/doi.org\/10.1172\/jci.insight.140532.","journal-title":"JCI Insight"},{"issue":"11","key":"756_CR104","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1111\/dom.15216","volume":"25","author":"LS Gasbjerg","year":"2023","unstructured":"Gasbjerg LS, Rosenkilde MM, Meier JJ, Holst JJ, Knop FK. The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide. Diabetes Obes Metab. 2023;25(11):3079\u201392. https:\/\/doi.org\/10.1111\/dom.15216.","journal-title":"Diabetes Obes Metab"},{"issue":"11\u201312","key":"756_CR105","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s12272-025-01575-9","volume":"48","author":"H Kim","year":"2025","unstructured":"Kim H, Kim SW, Choi C, Joo S, Kim G, Kim M, et al. Comparative analysis of LJ-4378 and tirzepatide in mouse models of obesity and weight regain. Arch Pharm Res. 2025;48(11\u201312):1441\u201359. https:\/\/doi.org\/10.1007\/s12272-025-01575-9.","journal-title":"Arch Pharm Res"},{"issue":"12","key":"756_CR106","doi-asserted-by":"publisher","first-page":"e146353","DOI":"10.1172\/JCI146353","volume":"131","author":"RJ Samms","year":"2021","unstructured":"Samms RJ, Christe ME, Collins KA, Pirro V, Droz BA, Holland AK, et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Invest. 2021;131(12):e146353. https:\/\/doi.org\/10.1172\/JCI146353.","journal-title":"J Clin Invest"},{"key":"756_CR107","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-025-09991-4","author":"W Masson","year":"2025","unstructured":"Masson W, Lobo M, Nogueira JP, Barbagelata L, Touzas P, Fr\u00edas JP. Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis. Rev Endocr Metab Disord. 2025. https:\/\/doi.org\/10.1007\/s11154-025-09991-4.","journal-title":"Rev Endocr Metab Disord"},{"key":"756_CR108","doi-asserted-by":"publisher","unstructured":"Mi L, Li T, Xiang X, Zhou Y, Xiong N, Chen Y, et al. Tirzepatide retention in iWAT with mesoporous polydopamine encapsulation enhances weight loss through leptin receptor signaling. J Adv Res. 2025;S2090\u201312322500692. https:\/\/doi.org\/10.1016\/j.jare.2025.09.009.","DOI":"10.1016\/j.jare.2025.09.009"},{"issue":"1","key":"756_CR109","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s13063-025-09045-9","volume":"26","author":"R Herman","year":"2025","unstructured":"Herman R, Jensterle M, Horvat S, Lezaic L, Snoj Z, Pusnik I, et al. Effect of tirzepatide-induced weight loss on adipose tissue in obesity: rationale and design of the randomized placebo-controlled TABFAT trial. Trials. 2025;26(1):300. https:\/\/doi.org\/10.1186\/s13063-025-09045-9.","journal-title":"Trials"},{"issue":"2","key":"756_CR110","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","volume":"106","author":"MK Thomas","year":"2021","unstructured":"Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021;106(2):388\u201396. https:\/\/doi.org\/10.1210\/clinem\/dgaa863.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"756_CR111","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.2337\/dc25-1306","volume":"48","author":"C Caussy","year":"2025","unstructured":"Caussy C, Cusi K, Rosenstock J, Bugianesi E, Thomas MK, Tang Y, et al. Relationship between metabolic and histological responses in people with MASH with and without type 2 diabetes: SYNERGY-NASH trial analysis. Diabetes Care. 2025;48(12):2074\u201383. https:\/\/doi.org\/10.2337\/dc25-1306.","journal-title":"Diabetes Care"},{"issue":"1","key":"756_CR112","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/dom.14553","volume":"24","author":"JM Wilson","year":"2022","unstructured":"Wilson JM, Lin Y, Luo MJ, Considine G, Cox AL, Bowsman LM, et al. Tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis. Diabetes Obes Metab. 2022;24(1):148\u201353. https:\/\/doi.org\/10.1111\/dom.14553.","journal-title":"Diabetes Obes Metab"},{"key":"756_CR113","doi-asserted-by":"publisher","first-page":"177095","DOI":"10.1016\/j.ejphar.2024.177095","volume":"985","author":"T Abdul-Rahman","year":"2024","unstructured":"Abdul-Rahman T, Roy P, Ahmed FK, Mueller-Gomez JL, Sarkar S, Garg N, et al. The power of three: Retatrutide\u2019s role in modern obesity and diabetes therapy. Eur J Pharmacol. 2024;985:177095. https:\/\/doi.org\/10.1016\/j.ejphar.2024.177095.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"756_CR114","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, Wu Q, Du Y, Gurbuz S, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2301972.","journal-title":"N Engl J Med"},{"key":"756_CR115","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13098-026-02116-0","volume":"18","author":"Q Li","year":"2026","unstructured":"Li Q, Cheng W, Zhang J, Ran S, Yu H, Zhou W, et al. Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair. Diabetol Metab Syndr. 2026;18:120. https:\/\/doi.org\/10.1186\/s13098-026-02116-0.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"756_CR116","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41574-020-00431-8","volume":"17","author":"GH Goossens","year":"2021","unstructured":"Goossens GH, Jocken JWE, Blaak EE. Sexual dimorphism in cardiometabolic health: the role of adipose tissue, muscle and liver. Nat Rev Endocrinol. 2021;17(1):47\u201366. https:\/\/doi.org\/10.1038\/s41574-020-00431-8.","journal-title":"Nat Rev Endocrinol"},{"key":"756_CR117","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s11920-025-01601-z","volume":"27","author":"A Ghanta","year":"2025","unstructured":"Ghanta A, Wilson E, Chao AM. Sex Differences in Obesity and Its Treatment. Curr Psychiatry Rep. 2025;27:278\u201385. https:\/\/doi.org\/10.1007\/s11920-025-01601-z.","journal-title":"Curr Psychiatry Rep"},{"key":"756_CR118","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s11695-019-04235-2","volume":"30","author":"AJ Sharples","year":"2020","unstructured":"Sharples AJ, Mahawar K. Systematic review and meta-analysis of randomized controlled trials comparing long-term outcomes of Roux-en-Y gastric bypass and sleeve gastrectomy. Obes Surg. 2020;30:664\u201372. https:\/\/doi.org\/10.1007\/s11695-019-04235-2.","journal-title":"Obes Surg"},{"issue":"5","key":"756_CR119","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s11695-012-0622-3","volume":"22","author":"R Peterli","year":"2012","unstructured":"Peterli R, Steinert RE, Woelnerhanssen B, Peters T, Christoffel-Courtin C, Gass M, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy. Obes Surg. 2012;22(5):740\u20138. https:\/\/doi.org\/10.1007\/s11695-012-0622-3.","journal-title":"Obes Surg"},{"key":"756_CR120","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.peptides.2015.08.013","volume":"77","author":"CL Meek","year":"2016","unstructured":"Meek CL, Lewis HB, Reimann F, Gribble FM, Park AJ. The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. Peptides. 2016;77:28\u201337. https:\/\/doi.org\/10.1016\/j.peptides.2015.08.013.","journal-title":"Peptides"},{"issue":"3","key":"756_CR121","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ando.2024.05.008","volume":"85","author":"S Lecoutre","year":"2024","unstructured":"Lecoutre S, Rebi\u00e8re C, Marcelin G, Cl\u00e9ment K. How does bariatric surgery remodel adipose tissue? Ann Endocrinol (Paris). 2024;85(3):175\u20138. https:\/\/doi.org\/10.1016\/j.ando.2024.05.008.","journal-title":"Ann Endocrinol (Paris)"},{"issue":"8","key":"756_CR122","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.2337\/diabetes.54.8.2277","volume":"54","author":"R Cancello","year":"2005","unstructured":"Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, et al. Reduction of macrophage infiltration in adipose tissue after weight loss. Diabetes. 2005;54(8):2277\u201386. https:\/\/doi.org\/10.2337\/diabetes.54.8.2277.","journal-title":"Diabetes"},{"issue":"9","key":"756_CR123","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1161\/ATVBAHA.111.225870","volume":"31","author":"H Zhang","year":"2011","unstructured":"Zhang H, Wang Y, Zhang J, Potter BJ, Sowers JR, Zhang C. Bariatric surgery reduces visceral adipose inflammation and improves endothelial function in type 2 diabetic mice. Arterioscler Thromb Vasc Biol. 2011;31(9):2063\u20139. https:\/\/doi.org\/10.1161\/ATVBAHA.111.225870.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"756_CR124","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1007\/s11695-017-2930-0","volume":"27","author":"M Tamez","year":"2017","unstructured":"Tamez M, Ramos-Barragan V, Mendoza-Lorenzo P, Arrieta-Joffe P, L\u00f3pez-Mart\u00ednez S, Rojano-Rodr\u00edguez ME, et al. Adipocyte size and leptin receptor expression after Roux-en-Y gastric bypass. Obes Surg. 2017;27(12):3330\u20132. https:\/\/doi.org\/10.1007\/s11695-017-2930-0.","journal-title":"Obes Surg"},{"issue":"7","key":"756_CR125","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1210\/jc.2018-02165","volume":"104","author":"P Katsogiannos","year":"2019","unstructured":"Katsogiannos P, Kamble PG, Boersma GJ, Karlsson FA, Lundkvist P, Sundbom M, et al. Early changes in adipose tissue morphology, gene expression, and metabolism after RYGB in patients with obesity and T2D. J Clin Endocrinol Metab. 2019;104(7):2601\u201313. https:\/\/doi.org\/10.1210\/jc.2018-02165.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"756_CR126","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1210\/jc.2015-3348","volume":"101","author":"Y Liu","year":"2016","unstructured":"Liu Y, Aron-Wisnewsky J, Marcelin G, Genser L, Le Naour G, Torcivia A, et al. Accumulation and Changes in Composition of Collagens in Subcutaneous Adipose Tissue After Bariatric Surgery. J Clin Endocrinol Metab. 2016;101(1):293\u2013304. https:\/\/doi.org\/10.1210\/jc.2015-3348.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"756_CR127","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.2337\/dc13-2395","volume":"37","author":"DP Andersson","year":"2014","unstructured":"Andersson DP, Eriksson Hogling D, Thorell A, Toft E, Qvisth V, N\u00e4slund E, et al. Changes in subcutaneous fat cell volume and insulin sensitivity after weight loss. Diabetes Care. 2014;37(7):1831\u20136. https:\/\/doi.org\/10.2337\/dc13-2395.","journal-title":"Diabetes Care"},{"issue":"9","key":"756_CR128","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1007\/s11695-019-03897-2","volume":"29","author":"AC Meyer-Gerspach","year":"2019","unstructured":"Meyer-Gerspach AC, Peterli R, Moor M, Mad\u00f6rin P, Sch\u00f6tzau A, Nabers D, et al. Quantification of Liver, Subcutaneous, and Visceral Adipose Tissues by MRI Before and After Bariatric Surgery. Obes Surg. 2019;29(9):2795\u2013805. https:\/\/doi.org\/10.1007\/s11695-019-03897-2.","journal-title":"Obes Surg"},{"issue":"1","key":"756_CR129","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12967-022-03485-6","volume":"20","author":"A Bouchard-Mercier","year":"2022","unstructured":"Bouchard-Mercier A, de Toro-Mart\u00edn J, Nadeau M, Lescelleur O, Lebel S, Richard D, et al. Molecular remodeling of adipose tissue is associated with metabolic recovery after weight loss surgery. J Transl Med. 2022;20(1):283. https:\/\/doi.org\/10.1186\/s12967-022-03485-6.","journal-title":"J Transl Med"},{"issue":"11","key":"756_CR130","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1210\/jc.2009-0925","volume":"94","author":"J Aron-Wisnewsky","year":"2009","unstructured":"Aron-Wisnewsky J, Tordjman J, Poitou C, Darakhshan F, Hugol D, Basdevant A, et al. Human adipose tissue macrophages: m1 and m2 cell surface markers in subcutaneous and omental depots and after weight loss. J Clin Endocrinol Metab. 2009;94(11):4619\u201323. https:\/\/doi.org\/10.1210\/jc.2009-0925.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"756_CR131","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40618-021-01626-0","volume":"45","author":"D Huang","year":"2022","unstructured":"Huang D, Zhang Z, Dong Z, Liu R, Huang J, Xu G. Caloric restriction and Roux-en-Y Gastric Bypass promote white adipose tissue browning in mice. J Endocrinol Invest. 2022;45(1):139\u201348. https:\/\/doi.org\/10.1007\/s40618-021-01626-0.","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"756_CR132","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1210\/clinem\/dgab072","volume":"106","author":"BW van der Kolk","year":"2021","unstructured":"van der Kolk BW, Muniandy M, Kaminska D, Alvarez M, Ko A, Miao Z, et al. Differential Mitochondrial Gene Expression in Adipose Tissue Following Weight Loss Induced by Diet or Bariatric Surgery. J Clin Endocrinol Metab. 2021;106(5):1312\u201324. https:\/\/doi.org\/10.1210\/clinem\/dgab072.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"756_CR133","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1113\/JP286103","volume":"603","author":"ACO Pinho","year":"2025","unstructured":"Pinho ACO, Lazaro A, Barbosa P, Porter C, Tralh\u00e3o JG, Carvalho E. Impact of the metabolic disease status in obesity and surgical weight loss on human adipose tissue bioenergetics. J Physiol. 2025;603(9):2583\u2013617. https:\/\/doi.org\/10.1113\/JP286103.","journal-title":"J Physiol"},{"issue":"7","key":"756_CR134","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1053\/j.gastro.2010.02.059","volume":"138","author":"MA Stefater","year":"2010","unstructured":"Stefater MA, P\u00e9rez-Tilve D, Chambers AP, Wilson-P\u00e9rez HE, Sandoval DA, Berger J, et al. Sleeve gastrectomy induces loss of weight and fat mass in obese rats, but does not affect leptin sensitivity. Gastroenterology. 2010;138(7):2426\u201336. https:\/\/doi.org\/10.1053\/j.gastro.2010.02.059.","journal-title":"Gastroenterology"},{"issue":"3","key":"756_CR135","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1210\/jc.2006-1839","volume":"92","author":"DG Haider","year":"2007","unstructured":"Haider DG, Schindler K, Prager G, Bohdjalian A, Luger A, Wolzt M, et al. Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. J Clin Endocrinol Metab. 2007;92(3):1168\u201371. https:\/\/doi.org\/10.1210\/jc.2006-1839.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"756_CR136","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1055\/s-0033-1347248","volume":"121","author":"C Bachmayer","year":"2013","unstructured":"Bachmayer C, Lammert A, Hasenberg T, Hammes HP. Healthy obese and post bariatric patients - metabolic and vascular patterns. Exp Clin Endocrinol Diabetes. 2013;121(8):483\u20137. https:\/\/doi.org\/10.1055\/s-0033-1347248.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"756_CR137","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13098-019-0511-1","volume":"12","author":"X Wang","year":"2020","unstructured":"Wang X, Huang Y, Gao J, Sun H, Jayachandran M, Qu S. Changes of serum retinol-binding protein 4 associated with improved insulin resistance after laparoscopic sleeve gastrectomy in Chinese obese patients. Diabetol Metab Syndr. 2020;12:7. https:\/\/doi.org\/10.1186\/s13098-019-0511-1.","journal-title":"Diabetol Metab Syndr"},{"issue":"5","key":"756_CR138","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.soard.2011.01.044","volume":"7","author":"B Woelnerhanssen","year":"2011","unstructured":"Woelnerhanssen B, Peterli R, Steinert RE, Peters T, Borb\u00e9ly Y, Beglinger C. Effects of postbariatric surgery weight loss on adipokines and metabolic parameters: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy\u2013a prospective randomized trial. Surg Obes Relat Dis. 2011;7(5):561\u20138. https:\/\/doi.org\/10.1016\/j.soard.2011.01.044","journal-title":"Surg Obes Relat Dis"},{"issue":"4","key":"756_CR139","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1055\/a-1129-6785","volume":"52","author":"M Askarpour","year":"2020","unstructured":"Askarpour M, Alizadeh S, Hadi A, Symonds ME, Miraghajani M, Sheikhi A, et al. Effect of Bariatric Surgery on the Circulating Level of Adiponectin, Chemerin, Plasminogen Activator Inhibitor-1, Leptin, Resistin, and Visfatin: A Systematic Review and Meta-Analysis. Horm Metab Res. 2020;52(4):207\u201315. https:\/\/doi.org\/10.1055\/a-1129-6785.","journal-title":"Horm Metab Res"},{"key":"756_CR140","doi-asserted-by":"publisher","first-page":"12809","DOI":"10.1038\/s41598-021-92254-4","volume":"11","author":"P Mousapour","year":"2021","unstructured":"Mousapour P, Tasdighi E, Khalaj A, et al. Sex disparity in laparoscopic bariatric surgery outcomes: a matched-pair cohort analysis. Sci Rep. 2021;11:12809. https:\/\/doi.org\/10.1038\/s41598-021-92254-4.","journal-title":"Sci Rep"},{"key":"756_CR141","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jss.2024.04.050","volume":"299","author":"AM Hider","year":"2024","unstructured":"Hider AM, Bonham A, Carlin A, Finks J, Ghaferi A, Varban O, Ehlers AP. Association of Sex Differences on Weight Loss and Complications Following Bariatric Surgery. J Surg Res. 2024;299:359\u201365. https:\/\/doi.org\/10.1016\/j.jss.2024.04.050.","journal-title":"J Surg Res"},{"issue":"6 Pt 2","key":"756_CR142","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S1262-3636(09)73458-5","volume":"35","author":"B Laferr\u00e8re","year":"2009","unstructured":"Laferr\u00e8re B. Effect of gastric bypass surgery on the incretins. Diabetes Metab. 2009;35(6 Pt 2):513\u20137. https:\/\/doi.org\/10.1016\/S1262-3636(09)73458-5.","journal-title":"Diabetes Metab"},{"issue":"Suppl 1","key":"756_CR143","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1038\/ijosup.2016.8","volume":"6","author":"B Laferr\u00e8re","year":"2016","unstructured":"Laferr\u00e8re B. Bariatric surgery and obesity: influence on the incretins. Int J Obes Suppl. 2016;6(Suppl 1):S32\u20136. https:\/\/doi.org\/10.1038\/ijosup.2016.8.","journal-title":"Int J Obes Suppl"},{"issue":"1","key":"756_CR144","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2337\/dc11-1472","volume":"35","author":"BJ Van der Schueren","year":"2012","unstructured":"Van der Schueren BJ, Homel P, Alam M, Agenor K, Wang G, Reilly D, et al. Magnitude and variability of the glucagon-like peptide-1 response in patients with type 2 diabetes up to 2 years following gastric bypass surgery. Diabetes Care. 2012;35(1):42\u20136. https:\/\/doi.org\/10.2337\/dc11-1472.","journal-title":"Diabetes Care"},{"issue":"5","key":"756_CR145","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1210\/er.2018-00183","volume":"40","author":"JD Douros","year":"2019","unstructured":"Douros JD, Tong J, D\u2019Alessio DA. The Effects of Bariatric Surgery on Islet Function, Insulin Secretion, and Glucose Control. Endocr Rev. 2019;40(5):1394\u2013423. https:\/\/doi.org\/10.1210\/er.2018-00183.","journal-title":"Endocr Rev"},{"issue":"5","key":"756_CR146","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1210\/jc.2005-0904","volume":"91","author":"R Morinigo","year":"2006","unstructured":"Morinigo R, Moiz\u00e9 V, Musri M, Lacy AM, Navarro S, Mar\u00edn JL, et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2006;91(5):1735\u201340. https:\/\/doi.org\/10.1210\/jc.2005-0904.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"756_CR147","doi-asserted-by":"publisher","first-page":"E923","DOI":"10.1152\/ajpendo.00422.2010","volume":"300","author":"M Speck","year":"2011","unstructured":"Speck M, Cho YM, Asadi A, Rubino F, Kieffer TJ. Duodenal-jejunal bypass protects GK rats from {beta}-cell loss and aggravation of hyperglycemia and increases enteroendocrine cells coexpressing GIP and GLP-1. Am J Physiol Endocrinol Metab. 2011;300(5):E923\u201332. https:\/\/doi.org\/10.1152\/ajpendo.00422.2010.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"9","key":"756_CR148","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1136\/gut.2010.234708","volume":"60","author":"JV Li","year":"2011","unstructured":"Li JV, Ashrafian H, Bueter M, Kinross J, Sands C, le Roux CW, et al. Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut. 2011;60(9):1214\u201323. https:\/\/doi.org\/10.1136\/gut.2010.234708.","journal-title":"Gut"},{"issue":"7","key":"756_CR149","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.2337\/db06-0068","volume":"55","author":"C Guidone","year":"2006","unstructured":"Guidone C, Manco M, Valera-Mora E, Iaconelli A, Gniuli D, Mari A, et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes. 2006;55(7):2025\u201331. https:\/\/doi.org\/10.2337\/db06-0068.","journal-title":"Diabetes"},{"issue":"1","key":"756_CR150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/000313480407000101","volume":"70","author":"RH Clements","year":"2004","unstructured":"Clements RH, Gonzalez QH, Long CI, Wittert G, Laws HL. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am Surg. 2004;70(1):1\u20134. discussion 4\u20135. PMID: 14964537.","journal-title":"Am Surg"},{"issue":"3","key":"756_CR151","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2337\/dc08-1314","volume":"32","author":"S Salinari","year":"2009","unstructured":"Salinari S, Bertuzzi A, Asnaghi S, Guidone C, Manco M, Mingrone G, et al. First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery. Diabetes Care. 2009;32(3):375\u201380. https:\/\/doi.org\/10.2337\/dc08-1314.","journal-title":"Diabetes Care"},{"key":"756_CR152","doi-asserted-by":"publisher","first-page":"1624001","DOI":"10.3389\/fendo.2025.1624001","volume":"16","author":"S Andrade","year":"2025","unstructured":"Andrade S, Lobato CB, Machado M, Hartmann B, Holst JJ, Almeida RF, et al. GLP-1 and GIP may play a role in long-term weight trajectories after gastric bypass. Front Endocrinol (Lausanne). 2025;16:1624001. https:\/\/doi.org\/10.3389\/fendo.2025.1624001.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"756_CR153","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1002\/oby.23563","volume":"30","author":"S Sarma","year":"2022","unstructured":"Sarma S, Palcu P. Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: A systematic review and meta-analysis. Obes (Silver Spring). 2022;30(11):2111\u201321. https:\/\/doi.org\/10.1002\/oby.23563.","journal-title":"Obes (Silver Spring)"},{"key":"756_CR154","doi-asserted-by":"publisher","first-page":"e085304","DOI":"10.1136\/bmj-2025-085304","volume":"392","author":"S West","year":"2026","unstructured":"West S, Scragg J, Aveyard P, Oke JL, Willis L, Haffner SJP, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026;392:e085304. https:\/\/doi.org\/10.1136\/bmj-2025-085304.","journal-title":"BMJ"},{"key":"756_CR155","doi-asserted-by":"publisher","unstructured":"Sabatella L, Ortega PM, Azc\u00e1rate VV, Sastre FR, Pagola AU, Ahmed A et al. Comparative efficacy of metabolic\/bariatric surgery versus GLP-1 receptor agonists: a network meta-analysis of randomized controlled trials. Obesity (Silver Spring). 2025;1. https:\/\/doi.org\/10.1002\/oby.70100","DOI":"10.1002\/oby.70100"},{"issue":"6","key":"756_CR156","doi-asserted-by":"publisher","first-page":"e2415392","DOI":"10.1001\/jamanetworkopen.2024.15392","volume":"7","author":"D Dicker","year":"2024","unstructured":"Dicker D, Sagy YW, Ramot N, Battat E, Greenland P, Arbel R, et al. Bariatric Metabolic Surgery vs Glucagon-Like Peptide-1 Receptor Agonists and Mortality. JAMA Netw Open. 2024;7(6):e2415392. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.15392.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"756_CR157","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41366-023-01254-z","volume":"47","author":"E Stenberg","year":"2023","unstructured":"Stenberg E, N\u00e4slund E. Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment. Int J Obes (Lond). 2023;47(4):251\u20136. https:\/\/doi.org\/10.1038\/s41366-023-01254-z.","journal-title":"Int J Obes (Lond)"},{"issue":"2","key":"756_CR158","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s11695-025-08415-1","volume":"36","author":"H Chen","year":"2026","unstructured":"Chen H, Guo X, Long T, Li M. Recurrent weight gain after weight loss induced by lifestyle intervention, metabolic and bariatric surgery, or semaglutide in adults with obesity: a systematic review of randomized controlled trials. Obes Surg. 2026;36(2):792\u2013803. https:\/\/doi.org\/10.1007\/s11695-025-08415-1.","journal-title":"Obes Surg"},{"key":"756_CR159","doi-asserted-by":"publisher","first-page":"969176440","DOI":"10.1016\/j.ejphar.2024.176440","volume":"15","author":"X Duan","year":"2024","unstructured":"Duan X, Zhang L, Liao Y, Lin Z, Guo C, Luo S, Wang F, Zou Z, Zeng Z, Chen C, Qiu J. Semaglutide alleviates gut microbiota dysbiosis induced by a high-fat diet. Eur J Pharmacol. 2024;15:969176440. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176440.","journal-title":"Eur J Pharmacol"},{"key":"756_CR160","doi-asserted-by":"publisher","unstructured":"Wang R, Lin Z, He M, Liao Y, Xu Y, Chen C, Duan X, Jiang X, Qiu J. The role of gut microbiota in Tirzepatide-mediated alleviation of high-fat diet-induced obesity. Eur J Pharmacol. 2025;51002177827. https:\/\/doi.org\/10.1016\/j.ejphar.2025.177827.","DOI":"10.1016\/j.ejphar.2025.177827"},{"issue":"5","key":"756_CR161","doi-asserted-by":"publisher","first-page":"101051","DOI":"10.1016\/j.xcrm.2023.101051","volume":"16","author":"J Yadav","year":"2023","unstructured":"Yadav J, Liang T, Qin T, Nathan N, Schwenger KJP, Pickel L, et al. Gut microbiome modified by bariatric surgery improves insulin sensitivity and correlates with increased brown fat activity and energy expenditure. Cell Rep Med. 2023;16(5):101051. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101051.","journal-title":"Cell Rep Med"},{"issue":"1","key":"756_CR162","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00423-025-03831-4","volume":"410","author":"YW Tan","year":"2025","unstructured":"Tan YW, Shang M, Davis S, Gananadha S. GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis. Langenbecks Arch Surg. 2025;410(1):295. https:\/\/doi.org\/10.1007\/s00423-025-03831-4.","journal-title":"Langenbecks Arch Surg"},{"issue":"5","key":"756_CR163","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/oby.23736","volume":"31","author":"N Murvelashvili","year":"2023","unstructured":"Murvelashvili N, Xie L, Schellinger JN, Mathew MS, Marroquin EM, Lingvay I, et al. Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence. Obes (Silver Spring). 2023;31(5):1280\u20139. https:\/\/doi.org\/10.1002\/oby.23736.","journal-title":"Obes (Silver Spring)"},{"issue":"4","key":"756_CR164","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s11695-024-07137-0","volume":"34","author":"M Jamal","year":"2024","unstructured":"Jamal M, Alhashemi M, Dsouza C, Al-Hassani S, Qasem W, Almazeedi S, et al. Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy: A Retrospective Cohort Study. Obes Surg. 2024;34(4):1324\u201332. https:\/\/doi.org\/10.1007\/s11695-024-07137-0.","journal-title":"Obes Surg"},{"key":"756_CR165","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/s2213-8587(19)30157-3","volume":"7","author":"AD Miras","year":"2019","unstructured":"Miras AD, P\u00e9rez-Pevida B, Aldhwayan M, et al. Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7:549\u201359. https:\/\/doi.org\/10.1016\/s2213-8587(19)30157-3.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"756_CR166","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-020-04850-4","author":"U Thakur","year":"2020","unstructured":"Thakur U, Bhansali A, Gupta R, Rastogi A. Liraglutide augments weight loss after laparoscopic sleeve gastrectomy: a randomised, double-blind, placebo-control study. Obes Surg. 2020. https:\/\/doi.org\/10.1007\/s11695-020-04850-4.","journal-title":"Obes Surg"},{"key":"756_CR167","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s11695-021-05884-y","volume":"32","author":"W Elhag","year":"2022","unstructured":"Elhag W, El Ansari W. Effectiveness and safety of liraglutide in managing inadequate weight loss and weight regain after primary and revisional bariatric surgery: anthropometric and cardiometabolic outcomes. Obes Surg. 2022;32:1005\u201315. https:\/\/doi.org\/10.1007\/s11695-021-05884-y.","journal-title":"Obes Surg"},{"key":"756_CR168","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-022-06211-9","author":"A Lautenbach","year":"2022","unstructured":"Lautenbach A, Wernecke M, Huber TB, et al. The potential of semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery\u2014a retrospective analysis. Obes Surg. 2022. https:\/\/doi.org\/10.1007\/s11695-022-06211-9.","journal-title":"Obes Surg"},{"key":"756_CR169","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamasurg.2023.2930","volume":"158","author":"J Mok","year":"2023","unstructured":"Mok J, Adeleke MO, Brown A, et al. Safety and efficacy of liraglutide, 3.0\u00a0mg, once daily vs placebo in patients with poor weight loss following metabolic surgery: the BARI-OPTIMISE randomized clinical trial. JAMA Surg. 2023;158:1003\u201311. https:\/\/doi.org\/10.1001\/jamasurg.2023.2930.","journal-title":"JAMA Surg"},{"issue":"4","key":"756_CR170","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s11695-023-06484-8","volume":"33","author":"AB Jensen","year":"2023","unstructured":"Jensen AB, Renstr\u00f6m F, Acz\u00e9l S, Folie P, Biraima-Steinemann M, Beuschlein F, et al. Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study. Obes Surg. 2023;33(4):1017\u201325. https:\/\/doi.org\/10.1007\/s11695-023-06484-8.","journal-title":"Obes Surg"},{"issue":"11","key":"756_CR171","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jamasurg.2025.3590","volume":"160","author":"TS Barrett","year":"2025","unstructured":"Barrett TS, Hafermann JO, Richards S, LeJeune K, Eid GM. Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists. JAMA Surg. 2025;160(11):1232\u20139. https:\/\/doi.org\/10.1001\/jamasurg.2025.3590.","journal-title":"JAMA Surg"},{"issue":"9","key":"756_CR172","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/j.cmet.2021.07.018","volume":"33","author":"J B\u00e4ckdahl","year":"2021","unstructured":"B\u00e4ckdahl J, Franz\u00e9n L, Massier L, Li Q, Jalkanen J, Gao H, et al. Spatial mapping reveals human adipocyte subpopulations with distinct sensitivities to insulin. Cell Metab. 2021;33(9):1869\u2013e18826. https:\/\/doi.org\/10.1016\/j.cmet.2021.07.018.","journal-title":"Cell Metab"},{"issue":"3","key":"756_CR173","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41591-026-04204-0","volume":"32","author":"SB Heymsfield","year":"2026","unstructured":"Heymsfield SB, Aronne LJ, Montgomery P, Klickstein LB, Coleman LA, Dole K, et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nat Med. 2026;32(3):869\u201382. https:\/\/doi.org\/10.1038\/s41591-026-04204-0.","journal-title":"Nat Med"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-026-00756-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-026-00756-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-026-00756-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:21:34Z","timestamp":1789021294000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13679-026-00756-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":173,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["756"],"URL":"https:\/\/doi.org\/10.1007\/s13679-026-00756-x","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"78"}}